Literature DB >> 7055951

On individual reference intervals based on a longitudinal study of plasma proteins and lipids in healthy subjects, and their possible clinical application.

N E Raun, B B Møller, U Back, I Gad.   

Abstract

In a longitudinal study, we determined interindividual and intra-individual variation in 20 plasma proteins and lipids and in other blood constituents by analysis of variance. Blood from 20 healthy subjects was sampled monthly for six months, a rigorous blood-sampling technique being applied. The mean proportion of interindividual variation differed for each blood constituent, ranging from 22 to 91% of the total variation. The possible clinical application of individual reference intervals of this homeostatic model was demonstrated by the fact that they were exceeded in individual cases of upper respiratory tract infection. Concordance between individual reference intervals in healthy controls and in patients--as exemplified in two chronic diseases, multiple sclerosis and chronic inactive pyelonephritis--suggests that the use of individual intervals in (chronic) disease is valid, even when derived from healthy persons. Additionally, sex- and age-related differences were significant for some constituents.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7055951

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  3 in total

1.  The long-term biological variability of fasting plasma glucose and serum fructosamine in healthy Beagle dogs.

Authors:  A L Jensen; H Aaes; L Iversen; T K Petersen
Journal:  Vet Res Commun       Date:  1999-03       Impact factor: 2.459

2.  Alpha 2-macroglobulin and fibrinogen modulate inflammatory edema in man.

Authors:  J van Gool; H van Vugt; E de Bont
Journal:  Inflammation       Date:  1990-06       Impact factor: 4.092

3.  Profiles of acute-phase reactants and clinical significance of alpha 2-macroglobulin in acute hepatitis B.

Authors:  J Van Gool
Journal:  Inflammation       Date:  1983-09       Impact factor: 4.092

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.